Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group

Elen Provenzano, Veerle Bossuyt, Giuseppe Viale, David Cameron, Sunil Badve, Carsten Denkert, Gaëtan Macgrogan, Frédérique Penault-Llorca, Judy Boughey, Giuseppe Curigliano, J. Michael Dixon, Laura Esserman, Gerd Fastner, Thorsten Kuehn, Florentia Peintinger, Gunter Von Minckwitz, Julia White, Wei Yang, W. Fraser Symmans

Research output: Contribution to journalReview article

94 Scopus citations

Abstract

Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of survival after neoadjuvant therapy. Thus, pathological complete response has become a primary end point for clinical trials. However, there is a current lack of uniformity in the definition of pathological complete response. A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting. An international working group was convened to develop practical recommendations for the pathologic assessment of residual disease in neoadjuvant clinical trials of breast cancer and information expected from pathology reports. Systematic sampling of areas identified by informed mapping of the specimen and close correlation with radiological findings is preferable to overly exhaustive sampling, and permits taking tissue samples for translational research. Controversial areas are discussed, including measurement of lesion size, reporting of lymphovascular space invasion and the presence of isolated tumor cells in lymph nodes after neoadjuvant therapy, and retesting of markers after treatment. If there has been a pathological complete response, this must be clearly stated, and the presence/absence of residual ductal carcinoma in situ must be described. When there is residual invasive carcinoma, a comment must be made as to the presence/absence of chemotherapy effect in the breast and lymph nodes. The Residual Cancer Burden is the preferred method for quantifying residual disease in neoadjuvant clinical trials in breast cancer; other methods can be included per trial protocols and regional preference. Posttreatment tumor staging using the Tumor-Node-Metastasis system should be included. These recommendations for standardized pathological evaluation and reporting of neoadjuvant breast cancer specimens should improve prognostication for individual patients and allow comparison of treatment outcomes within and across clinical trials.

Original languageEnglish (US)
Pages (from-to)1185-1201
Number of pages17
JournalModern Pathology
Volume28
Issue number9
DOIs
StatePublished - Sep 3 2015

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group'. Together they form a unique fingerprint.

  • Cite this

    Provenzano, E., Bossuyt, V., Viale, G., Cameron, D., Badve, S., Denkert, C., Macgrogan, G., Penault-Llorca, F., Boughey, J., Curigliano, G., Dixon, J. M., Esserman, L., Fastner, G., Kuehn, T., Peintinger, F., Von Minckwitz, G., White, J., Yang, W., & Symmans, W. F. (2015). Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group. Modern Pathology, 28(9), 1185-1201. https://doi.org/10.1038/modpathol.2015.74